drugset / Trial / NCT02306291
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.
Timeline
- Start
- 2015-03
- Primary completion
- 2017-12
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Uproleselan | Small molecule | 5 mg/kg | — |
| Subject | Uproleselan | Small molecule | 10 mg/kg | — |
| Subject | Uproleselan | Small molecule | 20 mg/kg | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Idarubicin | Small molecule | — | — |
| Background | Mitoxantrone | Small molecule | — | — |